SG11201610517PA - Heteroaryl compounds for kinase inhibition - Google Patents

Heteroaryl compounds for kinase inhibition

Info

Publication number
SG11201610517PA
SG11201610517PA SG11201610517PA SG11201610517PA SG11201610517PA SG 11201610517P A SG11201610517P A SG 11201610517PA SG 11201610517P A SG11201610517P A SG 11201610517PA SG 11201610517P A SG11201610517P A SG 11201610517PA SG 11201610517P A SG11201610517P A SG 11201610517PA
Authority
SG
Singapore
Prior art keywords
kinase inhibition
heteroaryl compounds
heteroaryl
compounds
kinase
Prior art date
Application number
SG11201610517PA
Other languages
English (en)
Inventor
Wei-Sheng Huang
Yongjin Gong
Feng Li
Nicholas E Bencivenga
David C Dalgarno
Anna Kohlmann
William C Shakespeare
Ranny M Thomas
Angela V West
Willmen Youngsaye
Yun Zhang
Tianjun Zhou
Xiaotian Zhu
Original Assignee
Ariad Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ariad Pharma Inc filed Critical Ariad Pharma Inc
Publication of SG11201610517PA publication Critical patent/SG11201610517PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
SG11201610517PA 2014-06-19 2015-05-13 Heteroaryl compounds for kinase inhibition SG11201610517PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462014500P 2014-06-19 2014-06-19
PCT/US2015/030576 WO2015195228A1 (fr) 2014-06-19 2015-05-13 Composés hétéroaryle d'inhibition de la kinase

Publications (1)

Publication Number Publication Date
SG11201610517PA true SG11201610517PA (en) 2017-01-27

Family

ID=54935960

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913753VA SG10201913753VA (en) 2014-06-19 2015-05-13 Heteroaryl compounds for kinase inhibition
SG11201610517PA SG11201610517PA (en) 2014-06-19 2015-05-13 Heteroaryl compounds for kinase inhibition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913753VA SG10201913753VA (en) 2014-06-19 2015-05-13 Heteroaryl compounds for kinase inhibition

Country Status (41)

Country Link
US (4) US10227342B2 (fr)
EP (3) EP3157916B1 (fr)
JP (5) JP6230205B2 (fr)
KR (2) KR102628356B1 (fr)
CN (2) CN106559991B (fr)
AP (1) AP2017009690A0 (fr)
AU (2) AU2015277786B2 (fr)
BR (1) BR112016029662B1 (fr)
CA (1) CA2949793C (fr)
CL (2) CL2016003222A1 (fr)
CO (1) CO2017000386A2 (fr)
CR (1) CR20170011A (fr)
CU (1) CU20160185A7 (fr)
CY (1) CY1121359T1 (fr)
DK (1) DK3157916T3 (fr)
EA (1) EA034691B1 (fr)
EC (1) ECSP17003553A (fr)
ES (1) ES2715500T3 (fr)
GE (2) GEP20197011B (fr)
HR (1) HRP20190407T1 (fr)
HU (1) HUE042390T2 (fr)
IL (2) IL274159B2 (fr)
LT (1) LT3157916T (fr)
MA (2) MA54253A (fr)
ME (1) ME03334B (fr)
MX (1) MX361802B (fr)
MY (1) MY186839A (fr)
NZ (1) NZ726723A (fr)
PE (1) PE20170268A1 (fr)
PH (1) PH12016502453A1 (fr)
PL (1) PL3157916T3 (fr)
PT (1) PT3157916T (fr)
RS (1) RS58541B1 (fr)
SA (1) SA516380531B1 (fr)
SG (2) SG10201913753VA (fr)
SI (1) SI3157916T1 (fr)
TN (1) TN2016000560A1 (fr)
TR (1) TR201903322T4 (fr)
UA (1) UA121657C2 (fr)
WO (1) WO2015195228A1 (fr)
ZA (1) ZA201608224B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
ES2715500T3 (es) * 2014-06-19 2019-06-04 Ariad Pharma Inc Compuestos de heteroarilo para la inhibición de la quinasa
CN113121575A (zh) * 2014-08-25 2021-07-16 四川海思科制药有限公司 一种(取代的苯基)(取代的嘧啶)胺基衍生物及其制备方法和药物用途
CN106661000B (zh) * 2014-10-11 2019-04-09 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
CN111170998B (zh) 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
WO2016094821A2 (fr) 2014-12-11 2016-06-16 Beta Pharma, Inc. Dérivés de 2-anilinopyrimidine substitués utilisés comme modulateurs de l'egfr
US20210323976A1 (en) * 2015-05-13 2021-10-21 Ariad Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
WO2017035753A1 (fr) * 2015-08-31 2017-03-09 无锡双良生物科技有限公司 2-arylamino pyridine, dérivé de pyridine ou de triazine, leur procédé de préparation et leur utilisation
CN106117185B (zh) * 2015-08-31 2017-11-07 广州必贝特医药技术有限公司 2,4‑二含氮基团取代嘧啶类化合物及其制备方法和应用
AU2016379292B2 (en) 2015-12-24 2021-03-25 Kyowa Kirin Co., Ltd. α, β unsaturated amide compound
WO2017120429A1 (fr) 2016-01-07 2017-07-13 CS Pharmasciences, Inc. Inhibiteurs sélectifs de mutants cliniquement importants de la tyrosine kinase de l'egfr
WO2017119732A1 (fr) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Dispositif électronique, et son procédé de fonctionnement
CN106995435B (zh) * 2016-01-22 2018-06-08 焦玉奇 2-(2,4,5-取代苯胺)嘧啶衍生物
TWI745345B (zh) * 2016-02-01 2021-11-11 瑞典商阿斯特捷利康公司 製備奧希替尼（osimertinib，azd9291）或其鹽及「azd9291苯胺」或其鹽的改良方法
JP7112957B2 (ja) 2016-03-09 2022-08-04 ベイジン パーカンズ オンコロジー カンパニー リミテッド 腫瘍細胞懸濁培養及び関連方法
ES2857805T3 (es) * 2016-03-22 2021-09-29 Jiangsu Hansoh Pharmaceutical Group Co Ltd Forma policristalina de base libre o sal ácida del inhibidor de EGFR, método de preparación y aplicación
CA3023228A1 (fr) 2016-05-11 2017-11-16 Beta Pharma, Inc. Derives de 2-anilinopyrimidine utilises en tant qu'agents therapeutiques pour le traitement de cancers du cerveau
MX2018013413A (es) 2016-05-26 2019-06-06 Zeno Royalties & Milestones Llc Compuestos inhibidores de egfr.
SG11201810976TA (en) * 2016-06-17 2019-01-30 Beta Pharma Inc Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
WO2018019204A1 (fr) * 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 Composé amino pyrimidine pour inhiber l'activité de la protéine tyrosine kinase
CN107793413B (zh) * 2016-09-05 2021-09-28 上海科州药物研发有限公司 嘧啶杂环化合物及其制备方法和应用
CN106432231B (zh) * 2016-09-09 2018-06-12 无锡佰翱得生物科学有限公司 Azd9291的药用盐、及其晶型和制备方法
CN106432249B (zh) * 2016-09-30 2018-12-04 陕西科技大学 一类吡咯并[2，1-f][1，2，4]三嗪母核化合物的合成及其医药用途
JOP20190073A1 (ar) 2016-10-31 2019-04-07 Taiho Pharmaceutical Co Ltd مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20
CN108057036B (zh) * 2016-11-07 2023-06-13 正大天晴药业集团股份有限公司 一种egfr抑制剂的固体药物组合物
CN108129342A (zh) * 2016-11-30 2018-06-08 浙江九洲药物科技有限公司 一种奥希替尼中间体及其制备方法
CN108503627A (zh) * 2017-04-19 2018-09-07 郑州泰基鸿诺医药股份有限公司 用作egfr抑制剂的2,4-二取代苯-1,5-二胺衍生物及其应用
CN106967050A (zh) * 2017-05-11 2017-07-21 北京工业大学 一种azd9291的制备方法
CN108864079B (zh) * 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
TWI765041B (zh) 2017-05-18 2022-05-21 瑞士商愛杜西亞製藥有限公司 作為pge2受體調節劑之苯基衍生物
UA125124C2 (uk) 2017-05-18 2022-01-12 Ідорсія Фармасьютікалз Лтд Піримідинові похідні як модулятори pge2 рецепторів
ES2963921T3 (es) * 2017-06-13 2024-04-03 Beijing Avlstone Biotechnology Co Ltd Compuestos de aminopirimidina, su método de preparación y uso de los mismos
WO2019010619A1 (fr) * 2017-07-10 2019-01-17 焦玉奇 Dérivé pyrimidine de 2-(aniline 2,4,5-substituée)
BR112020004000A2 (pt) 2017-09-01 2020-10-20 Taiho Pharmaceutical Co., Ltd. inibidor seletivo de egfr mutante no exon 18 e/ou exon 21
CN107556293B (zh) * 2017-09-19 2019-12-03 福建省微生物研究所 一种奥西替尼的合成工艺
AR113451A1 (es) * 2017-10-18 2020-05-06 Spectrum Pharmaceuticals Inc Inhibidores de tirosina quinasas de la familia de los egfr mutantes
EP3740207A4 (fr) 2018-01-16 2021-10-13 Syros Pharmaceuticals, Inc. Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
AU2019209475A1 (en) 2018-01-16 2020-08-20 Syros Pharmaceuticals, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
KR102170422B1 (ko) * 2018-01-25 2020-10-27 경동제약 주식회사 토파시티닙의 신규 염, 이의 제조방법 및 이를 포함하는 약학 조성물
CN108283628B (zh) * 2018-04-20 2021-01-01 南京康川济医药科技有限公司 一种抗癌药物微囊制剂及其制备方法
EP4234547A3 (fr) * 2018-05-14 2023-11-01 Takeda Pharmaceutical Company Limited Sels pharmaceutiques de dérivés de pyrimidine et méthode de traitement d'affections
CN116808044A (zh) * 2018-06-15 2023-09-29 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN110606842B (zh) * 2018-06-15 2021-06-01 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物的制备方法及其中间体
CN110698461B (zh) * 2018-07-09 2024-04-05 上海翰森生物医药科技有限公司 第三代egfr抑制剂的制备方法
CN110776495A (zh) * 2018-07-30 2020-02-11 罗赟 激酶抑制剂的晶型及其制备方法和用途
CN110790749B (zh) * 2018-08-03 2023-07-14 北京普祺医药科技股份有限公司 一种含氮杂环化合物、药物组合物以及其用途
CA3118324A1 (fr) 2018-11-01 2020-05-07 Syros Pharmaceuticals, Inc. Methodes de traitement du cancer chez des patients identifies par biomarqueurs avec des inhibiteurs non covalents de la kinase cycline-dependante 7 (cdk7)
JP7516029B2 (ja) * 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7536767B2 (ja) 2018-12-31 2024-08-20 バイオメア フュージョン，インコーポレイテッド メニン－ｍｌｌ相互作用の不可逆的阻害剤
WO2020142559A1 (fr) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibiteurs de l'interaction ménine-mll
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
CN109761960B (zh) * 2019-02-25 2021-08-31 江苏豪森药业集团有限公司 抗耐药抗肿瘤egfr抑制剂的制备方法
WO2020190119A1 (fr) 2019-03-19 2020-09-24 주식회사 보로노이 Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
CN111747950B (zh) * 2019-03-29 2024-01-23 深圳福沃药业有限公司 用于治疗癌症的嘧啶衍生物
CN111777620A (zh) * 2019-04-04 2020-10-16 山东轩竹医药科技有限公司 酪氨酸激酶抑制剂的新用途
CN109942550A (zh) * 2019-04-15 2019-06-28 广州医科大学附属第一医院（广州呼吸中心） 11c标记的egfr正电子示踪剂及其制备方法和应用
KR20220011663A (ko) * 2019-05-22 2022-01-28 상하이 한서 바이오메디컬 컴퍼니 리미티드 인돌 유도체-함유 억제제, 이의 제조 방법 또는 이의 적용
BR112021025764A2 (pt) * 2019-06-20 2022-02-01 Oncobix Co Ltd Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
CN114127058B (zh) * 2019-07-04 2024-06-25 深圳国顺康医药科技有限公司 一种杂环化合物、其药物组合物及用途
CN110283162B (zh) * 2019-07-09 2022-04-05 辽宁大学 一种表皮生长因子受体抑制剂及其应用
US11530196B2 (en) 2019-07-26 2022-12-20 China Resources Pharmaceutical Holdings Company Limited Pyrimidine compound acting on EGFR and ERBB2
TW202128670A (zh) * 2019-11-26 2021-08-01 大陸商上海翰森生物醫藥科技有限公司 含氮多環類衍生物抑制劑、其製備方法和應用
WO2021127456A1 (fr) 2019-12-19 2021-06-24 Rain Therapeutics Inc. Procédés d'inhibition de protéines réceptrices du facteur de croissance épidermique
CN115052881B (zh) 2020-02-03 2024-07-09 勃林格殷格翰国际有限公司 作为HER2抑制剂的[1,3]二嗪并[5,4-d]嘧啶
EP4100409B1 (fr) 2020-02-03 2024-08-28 Boehringer Ingelheim International GmbH [1,3]diazino[5,4-d]pyrimidines en tant qu'inhibiteurs de her2
CN115175902B (zh) * 2020-03-13 2024-07-26 郑州同源康医药有限公司 一类用作激酶抑制剂的化合物及其应用
CN111303125A (zh) * 2020-04-10 2020-06-19 天津法莫西医药科技有限公司 一种甲氧基取代吲哚-嘧啶类化合物及其制备方法
US11608343B2 (en) * 2020-04-24 2023-03-21 Boehringer Ingelheim International Gmbh Substituted pyrimido[5,4-d]pyrimidines as HER2 inhibitors
WO2021243596A1 (fr) * 2020-06-03 2021-12-09 InventisBio Co., Ltd. Composés d'aminopyrimidine, leurs procédés de préparation et leurs utilisations
CN115734968A (zh) * 2020-06-23 2023-03-03 深圳福沃药业有限公司 化合物的盐以及包含盐的药物组合物
CN113861195B (zh) * 2020-06-30 2022-11-18 上海和誉生物医药科技有限公司 一种多稠环egfr抑制剂及其制备方法和应用
CN112159392B (zh) * 2020-09-15 2021-11-23 南京雷正医药科技有限公司 取代嘧啶化合物及其药物组合物和该化合物的用途
CN115197203B (zh) * 2021-04-12 2024-06-25 上海医药工业研究院 苯胺嘧啶类化合物、其制备方法及应用
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2023277172A1 (fr) 2021-06-30 2023-01-05 Takeda Pharmaceutical Company Limited Procédé de préparation de sels pharmaceutiques de dérivés de pyrimidine
CA3229150A1 (fr) 2021-08-20 2023-02-23 Biomea Fusion, Inc. Formes cristallines de n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidine-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propene-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, un inhibiteur irreversible de menine-mll pour le traitement du cance
WO2023039470A1 (fr) * 2021-09-10 2023-03-16 Palvella Therapeutics, Inc. Compositions anhydres d'inhibiteurs d'egfr et procédés d'utilisation
CN114014847B (zh) * 2021-12-08 2023-11-03 滨州医学院 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用
CN114213339B (zh) * 2021-12-20 2023-10-31 苏州康纯医药科技有限公司 一种表皮细胞生长因子受体突变抑制剂的制备方法

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
KR890002631B1 (ko) 1984-10-04 1989-07-21 몬산토 캄파니 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
WO1987005898A2 (fr) 1986-03-31 1987-10-08 Rhone-Poulenc Nederlands B.V. Utilisation de composes derives de l'acide malonique pour retarder la croissance des plantes
AU7284387A (en) 1986-03-31 1987-10-20 Union Carbide Agricultural Products Company Inc. Use of malonic acid derivative compounds for increasing crop yield
CN1024544C (zh) 1986-03-31 1994-05-18 联合碳化农产化学品公司 协同的植物生长调节剂组合物
CA1283827C (fr) 1986-12-18 1991-05-07 Giorgio Cirelli Dispositif pour l'injection de formules liquides
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
WO1995024176A1 (fr) 1994-03-07 1995-09-14 Bioject, Inc. Dispositif de remplissage d'ampoule
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ATE198326T1 (de) 1995-04-20 2001-01-15 Pfizer Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
DE69632684T2 (de) 1995-06-27 2005-06-09 Takeda Pharmaceutical Co. Ltd. Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
EP0780386B1 (fr) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Inhibiteurs de métalloprotéases matricielles
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
YU1899A (sh) 1996-07-18 2000-03-21 Pfizer Inc. Inhibitori matričnih metaloproteaza na bazi fosfinata
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
DE69730093T2 (de) 1996-10-31 2006-07-20 Takeda Pharmaceutical Co. Ltd. Zubereitung mit verzögerter Freisetzung
ATE233088T1 (de) 1996-12-20 2003-03-15 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
ES2224277T3 (es) 1997-01-06 2005-03-01 Pfizer Inc. Derivados de sulfonas ciclicas.
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
KR100317146B1 (ko) 1997-02-03 2001-12-22 데이비드 존 우드 아릴술포닐아미노 히드록삼산 유도체
EP0966438A1 (fr) 1997-02-07 1999-12-29 Pfizer Inc. Derives du n-hxdroxy-beta-sulfonyl-propionamide et leur utilisation comme inhibiteurs des metalloproteases matrices
KR20000070923A (ko) 1997-02-11 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐 하이드록삼산 유도체
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
CN100415770C (zh) 2001-05-30 2008-09-03 诺瓦提斯公司 2－{[n－(2－氨基－3－(杂芳基或芳基)丙酰基)－氨基酰基]－氨基}－烷基硼酸衍生物
BR0307544A (pt) 2002-02-01 2004-12-07 Ariad Gene Therapeutics Inc Compostos contendo fósforos, componentes e composição bem como, sua utilização através de métodos de tratamentos
CA2485589A1 (fr) * 2002-05-14 2003-11-27 Baylor College Of Medicine Petites molecules inhibitrices de l'expression du gene her2
PT1761540T (pt) 2004-05-13 2016-12-07 Icos Corp Quinazolinonas como inibidores de fosfatidilinositol-3-cinase delta humana
US20080318974A1 (en) 2004-08-19 2008-12-25 Icos Corporation Compounds Useful for Inhibiting Chk1
US7973059B2 (en) 2005-10-21 2011-07-05 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP1948180B1 (fr) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Traitement combine du cancer comprenant des inhibiteurs de egfr/her2
TW200826843A (en) 2006-09-13 2008-07-01 Sumitomo Chemical Co Thiadiazole compound and use thereof
AU2007332493A1 (en) 2006-12-14 2008-06-19 Daiichi Sankyo Company, Limited Imidazothiazole derivatives
FR2911140B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de 2-anilino 4-heteroaryle pyrimides, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911138B1 (fr) 2007-01-05 2009-02-20 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2171090B1 (fr) 2007-06-08 2013-04-03 Genentech, Inc. Marqueurs d'expression de gène de résistance tumorale à un traitement par inhibiteur her2
EP2176249A2 (fr) 2007-07-02 2010-04-21 Boehringer Ingelheim International GmbH Nouveaux composés chimiques
FR2919869B1 (fr) 2007-08-09 2009-09-25 Sanofi Aventis Sa Nouveaux derives de n, n'-2,4-dianilinopyrimidines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
JP5869222B2 (ja) 2008-01-04 2016-02-24 インテリカイン， エルエルシー 特定の化学的実体、組成物および方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2228350A4 (fr) 2008-01-10 2010-12-29 Asahi Glass Co Ltd Verre, matière de revêtement pour dispositif émettant de la lumière et dispositif émettant de la lumière
EP2252293B1 (fr) 2008-03-14 2018-06-27 Intellikine, LLC Inhibiteurs de kinases, et procédés d utilisation associés
AU2009262068C1 (en) * 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
US9096611B2 (en) 2008-07-08 2015-08-04 Intellikine Llc Kinase inhibitors and methods of use
JP5731978B2 (ja) 2008-09-26 2015-06-10 インテリカイン， エルエルシー 複素環キナーゼ阻害剤
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
EP2396004A4 (fr) 2009-02-11 2012-07-25 Reaction Biology Corp Inhibiteurs de kinase sélectifs
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CA2760794C (fr) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Inhibiteurs d'egfr et procedes de traitement de troubles
WO2010132598A1 (fr) 2009-05-13 2010-11-18 Amgen Inc. Composés hétéroaryle en tant qu'inhibiteurs des pikk
WO2011082266A2 (fr) 2009-12-30 2011-07-07 Arqule, Inc. Composés hétérocycliques substitués
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
WO2012020215A1 (fr) 2010-08-09 2012-02-16 Centro Nacional De Investigaciones Oncológicas (Cnio) Amino-imidazolothiadiazoles destinés à être utilisés en tant qu'inhibiteurs de kinases protéiques ou lipidiques
AR083933A1 (es) 2010-11-19 2013-04-10 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
ES2536415T3 (es) 2010-11-19 2015-05-25 Incyte Corporation Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK
JP2014513724A (ja) 2011-05-16 2014-06-05 オーエスアイ・ファーマシューティカルズ，エルエルシー 融合二環キナーゼ阻害剤
CA2838186A1 (fr) 2011-06-08 2012-12-13 The Board Of Trustees Of The Leland Standford Junior University Blocages des interactions proteine d'echafaudage/kinase et applications dans le traitement du cancer
DK3686194T3 (da) * 2011-07-27 2021-11-22 Astrazeneca Ab 2-(2,4,5-substitueret-anilino)pyrimidinforbindelser
EP2647634A1 (fr) * 2012-04-02 2013-10-09 Noscira, S.A. Dérivés d'indole-pyrimidine et leurs utilisations thérapeutiques
AU2013204563B2 (en) * 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN104583194A (zh) 2012-05-11 2015-04-29 艾伯维公司 作为nampt抑制剂的哒嗪和吡啶衍生物
JP2015516436A (ja) 2012-05-11 2015-06-11 アッヴィ・インコーポレイテッド Ｎａｍｐｔ阻害薬
US20140371238A1 (en) 2013-03-13 2014-12-18 Flatley Discovery Lab Compounds and methods for the treatment of cystic fibrosis
TWI663166B (zh) * 2013-04-24 2019-06-21 健生藥品公司 新化合物
MX368781B (es) 2013-09-18 2019-10-16 Beijing Hanmi Pharmaceutical Co Ltd Compuesto inhibidor de las actividades de las cinasas btk y/o jak3.
CN104262328B (zh) 2013-09-18 2016-09-07 北京韩美药品有限公司 抑制btk和/或jak3激酶活性的化合物
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015140717A1 (fr) 2014-03-18 2015-09-24 Iteos Therapeutics Dérivés substitués par 3-indole, compositions pharmaceutiques et procédés d'utilisation
EP3143015B1 (fr) * 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Composés hétéroaryl pour l'inhibition de kinase
ES2715500T3 (es) * 2014-06-19 2019-06-04 Ariad Pharma Inc Compuestos de heteroarilo para la inhibición de la quinasa
GB201416754D0 (en) 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
CN106661000B (zh) 2014-10-11 2019-04-09 上海翰森生物医药科技有限公司 Egfr抑制剂及其制备和应用
TWI696617B (zh) 2015-04-28 2020-06-21 大陸商上海復尚慧創醫藥研究有限公司 特定蛋白質激酶抑制劑

Also Published As

Publication number Publication date
EP3778584A1 (fr) 2021-02-17
EA034691B1 (ru) 2020-03-06
EP3409669A1 (fr) 2018-12-05
IL274159B2 (en) 2024-03-01
DK3157916T3 (en) 2019-03-18
US20170197962A1 (en) 2017-07-13
JP2017521394A (ja) 2017-08-03
JP6230205B2 (ja) 2017-11-15
PT3157916T (pt) 2019-03-25
JP2021181486A (ja) 2021-11-25
HUE042390T2 (hu) 2019-06-28
AU2019206024A1 (en) 2019-08-01
IL274159A (en) 2020-06-30
KR102412037B1 (ko) 2022-06-22
KR102628356B1 (ko) 2024-01-24
HRP20190407T1 (hr) 2019-05-03
US10227342B2 (en) 2019-03-12
ME03334B (fr) 2019-10-20
CA2949793A1 (fr) 2015-12-23
MA40240A (fr) 2017-04-26
PE20170268A1 (es) 2017-04-21
JP2023052388A (ja) 2023-04-11
EP3157916A4 (fr) 2018-03-07
MA54253A (fr) 2021-09-22
KR20170016861A (ko) 2017-02-14
PL3157916T3 (pl) 2019-06-28
JP7212733B2 (ja) 2023-01-25
GEAP202014706A (en) 2020-02-10
IL274159B1 (en) 2023-11-01
EP3157916B1 (fr) 2018-12-12
WO2015195228A1 (fr) 2015-12-23
CO2017000386A2 (es) 2017-05-31
JP6546630B2 (ja) 2019-07-17
US9796712B2 (en) 2017-10-24
US20190218212A1 (en) 2019-07-18
EP3157916A1 (fr) 2017-04-26
JP2019194217A (ja) 2019-11-07
TN2016000560A1 (en) 2018-04-04
BR112016029662B1 (pt) 2023-10-24
GEP20197011B (en) 2019-08-12
IL248859B (en) 2020-05-31
SI3157916T1 (sl) 2019-05-31
LT3157916T (lt) 2019-04-10
US11958850B2 (en) 2024-04-16
CR20170011A (es) 2017-04-04
AU2015277786B2 (en) 2019-04-18
EP3409669B1 (fr) 2020-10-07
CL2017003103A1 (es) 2018-04-13
CN106559991A (zh) 2017-04-05
CU20160185A7 (es) 2017-05-10
GEP20207111B (en) 2020-05-25
EA201692261A1 (ru) 2017-05-31
ZA201608224B (en) 2019-04-24
ECSP17003553A (es) 2017-05-31
MA40240B1 (fr) 2019-03-29
TR201903322T4 (tr) 2019-03-21
AU2015277786A1 (en) 2016-12-22
CY1121359T1 (el) 2020-05-29
CA2949793C (fr) 2024-02-27
CN110526912A (zh) 2019-12-03
ES2715500T3 (es) 2019-06-04
RS58541B1 (sr) 2019-04-30
UA121657C2 (uk) 2020-07-10
MX361802B (es) 2018-12-14
AP2017009690A0 (en) 2017-01-31
US20230102829A1 (en) 2023-03-30
PH12016502453A1 (en) 2017-03-06
US20170253594A1 (en) 2017-09-07
SG10201913753VA (en) 2020-03-30
KR20220088522A (ko) 2022-06-27
IL248859A0 (en) 2017-01-31
CL2016003222A1 (es) 2017-10-13
MX2016016766A (es) 2017-04-27
MY186839A (en) 2021-08-25
NZ726723A (en) 2023-03-31
SA516380531B1 (ar) 2021-03-01
CN106559991B (zh) 2019-09-20
CN110526912B (zh) 2023-02-14
JP2018012712A (ja) 2018-01-25
BR112016029662A2 (pt) 2017-10-24

Similar Documents

Publication Publication Date Title
IL274159A (en) Heteroaryl compounds for kinase inhibition
HUS2400003I1 (hu) Kináz inhibitorként alkalmas vegyületek
HK1231475A1 (zh) -結合激酶抑制劑化合物
EP3143015A4 (fr) Composés hétéroaryl pour l'inhibition de kinase
HK1251567A1 (zh) 用於激酶抑制的雜芳基化合物
HK1249901B (zh) 用於抑制ror-gamma-t的化合物
GB201613945D0 (en) Compounds useful as kinase inhibitors
GB201522245D0 (en) Compounds useful as kinase inhibitors